Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated August 23, 2023, reports on the results of the ZOSTER-076 clinical trial. The trial is a post-licensure Phase IV study evaluating the efficacy and safety of Shingrix (Recombinant Zoster Vaccine or RZV) in preventing shingles (herpes zoster) in adults aged 50 and over in China.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory announcement regarding clinical trial data and does not contain financial statements.
Material Changes and Clinical Results
- Primary Efficacy: The trial demonstrated 100% vaccine efficacy (95% CI: 89.82%-100%) in preventing shingles.
- Cases Reported: Zero cases of shingles were reported among participants receiving RZV, compared to 31 cases in the placebo arm.
- Incidence Rates: The incidence rate was 0/1,000 person-years in the RZV arm versus 8.2/1,000 person-years in the placebo arm (p<0.0001).
- Study Population: The trial included 5,956 adults randomized 1:1 to RZV or placebo, conducted between 2021 and 2023.
- Safety Profile: The observed safety profile was consistent with the established profile of the vaccine and aligned with pivotal Phase III trials (ZOE-50 and ZOE-70).
Outlook, Commentary, and Risks
Management Commentary: GSK states these results affirm the efficacy and safety of RZV in preventing shingles in adults aged 50 and over, irrespective of sex, geographic region, or ancestry. The data supports the growing body of evidence for the vaccine in the Chinese market, where the population aged 65 and over is rapidly increasing.
Future Actions: Results from the ZOSTER-076 trial will be submitted for publication in a peer-reviewed scientific journal later in 2023.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in the company's Annual Report on Form 20-F for 2022, Q2 Results for 2023, and potential impacts of the COVID-19 pandemic.
Key Facts for Investor Verification
- Verify the commercial impact of the 100% efficacy data on Shingrix sales projections in China.
- Confirm the timeline for the peer-reviewed publication of the ZOSTER-076 trial results.
- Review the regulatory status of Shingrix in China following this post-licensure requirement fulfillment.
- Assess the potential market size given the estimated 6 million annual shingles cases in China and the aging demographic trends.